Details : NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain.
Product Name : NBI-1117570
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Details : Lecanemab (BAN2401) is an investigational humanized monoclonal antibody for Alzheimer's disease selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contribute to the neurodegenerat...
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : QP50ESO5RA
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Biohaven Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose and multiple ascending doses of subcutaneous HTL0022562 in healthy adult subj...
Product Name : HTL0022562
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : QP50ESO5RA
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Biohaven Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HTL0018318
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Allergan Aesthetics
Deal Size : $3,290.0 million
Deal Type : Termination
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
Details : AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the ...
Product Name : HTL0018318
Product Type : Other Small Molecule
Upfront Cash : $125.0 million
May 01, 2021
Lead Product(s) : HTL0018318
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Allergan Aesthetics
Deal Size : $3,290.0 million
Deal Type : Termination
Lead Product(s) : Relutrigine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Praxis Precision Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Praxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development
Details : Praxis will utilize the Ciitizen platform to provide deeper insights across disease populations through the analysis of real-world data, initially to inform the development of PRAX-222 and PRAX-562 in SCN2A developmental and epileptic encephalopathy (SCN...
Product Name : PRAX-562
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 16, 2021
Lead Product(s) : Relutrigine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Praxis Precision Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
Details : Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.
Product Name : AK1780
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
January 29, 2021
Sosei Heptares and Aditum Bio to Advance mGlu5 NAM Clinical Program for Neurological Diseases
Details : Tempero Bio will obtain exclusive global rights to a portfolio of potent, orally available metabotropic glutamate receptor 5 NAM modulators, including HTL0014242, which were precision-designed by Sosei Heptares using its GPCR Structure-Based Drug Design ...
Product Name : TMP-301
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 11, 2020